ANGPTL3-resistant humanized monoclonal antibody stably transfected strain and application thereof

A humanized monoclonal antibody cell line expressing high levels of anti-ANGPTL3 was constructed in CHO-K1Q cells using electroporation and multiple screening methods. This solved the problem of unstable expression levels and enabled efficient and stable monoclonal antibody production, suitable for various detection and therapeutic applications.

CN118909965AInactive Publication Date: 2024-11-08CHILDRENS HOSPITAL OF FUDAN UNIV +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411344774.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The expression of existing anti-ANGPTL3 humanized monoclonal antibodies relies on transient transfection technology, which leads to unstable expression levels and is not suitable for large-scale industrial production. Furthermore, differences in electrotransfection conditions result in inconsistent transfection efficiency.

Method used

The anti-ANGPTL3 humanized monoclonal antibody expression vector was introduced into host cells via electroporation. High-expression and stable and controllable anti-ANGPTL3 humanized monoclonal antibody cell lines were obtained through multiple screening methods. Gene cloning was performed using IN-FUSION technology, and screening was carried out in CHO-K1Q cells, including steps such as glutamine-free medium and MSX pressure screening.

Benefits of technology

High expression levels and stability of the anti-ANGPTL3 humanized monoclonal antibody were achieved, making it suitable for large-scale industrial production. The cell line FD36-A44 was screened, with an expression level of 3177.90 mg/L and high cell viability, making it suitable for various detection and therapeutic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005060660710000011
    Figure HDA0005060660710000011
  • Figure HDA0005060660710000012
    Figure HDA0005060660710000012
  • Figure HDA0005060660710000013
    Figure HDA0005060660710000013
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and particularly relates to an ANGPTL3 (anti-ANGPTL3) humanized monoclonal antibody stably transformed strain and application thereof. The anti-ANGPTL3 humanized monoclonal antibody expression vector is introduced into a host cell through electrotransfection, and a series of stable and controllable cell strains with high expression quantity are finally screened out through multiple times of screening. The invention further discloses an ANGPTL3 humanized monoclonal antibody based on the hybridoma cell, and the monoclonal antibody can be used for a reagent for detecting ANGPTL3 and can also be used for preparing a medicine for preventing and / or treating kidney diseases or metabolism-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to an anti-ANGPTL3 humanized monoclonal antibody stable strain and application thereof. Background Art

[0002] Angiopoietin-like protein-3 (ANGPTL3) was first proposed by Conklin et al. in 1999. It is a member of the angiotensin-like protein family, which is named for its structural similarity to angiotensin. The ANGPTL gene family encodes a class of secretory proteins, namely ANGPTL1-8, which have similar structures and a series of studies have confirmed that some members play an important role in lipid metabolism (Mattijssen F, Kersten S, Regulation of triglyceride metabolism by Angiopoietin-like proteins, Biochim Biophys Acta, 2012, 1821(5): 782-789.). ANGPTL3 is a sequence with a unique signal peptide molecular structure. Many studies have confirmed that it is mainly expressed in hepatocytes and is a key regulator of lipoprotein metabolism. It inhibits the activity of lipoprotein lipase and endothelial lipase (KERSTEN S.ANGPTL3 as therapeutic target[J].Curr Opin li-pidal,2021.32(6):335-341.), significantly increases the expression level of serum very low-density lipoprotein, and ultimately leads to a significant decrease in the decomposition of triglycerides (TG) and total cholesterol (TC), a significant increase in blood lipid levels, and then causes insulin resistance and angiogenesis disorders. ANGPTL3 is involved in the occurrence and development of a variety of metabolic-related diseases and has been considered by researchers to be a key factor in regulating the physiological metabolism of blood lipids in the body (KERSTEN S.Angiopoietin-like 3in lipoprotein metabolism[J].Nat Rev Enlocrinol,2017,13(12):731;GRAHAM MJ,LEE RG,BRANIT TA,etal.Candiovascular and metabolic elements of ANGPTl3 antisense oligonueleolides[J].EngI J Med,2017,377(3):222;XU YX,REDON V,YU H,et al.Role ofangiopoietin-like 3(ANGPTl3)in regulating plasa level of low-densitylipoproteincholesderol[J].Atherasclensis,2018,58(268):196.).Abnormally high expression of ANGPTL3 increases plasma lipid levels, further inducing the formation of foam cells and the proliferation and migration of vascular smooth muscle cells, leading to atherosclerosis (SUN T, ZHAN W, WEl L, et al. Cireulating ANGPTL3 and ANGPTL4 levels prediet cornary artery atheraselerasis severily[J]. Lipids Health Dis. 2021.20(1):154-162.).

[0003] So far, three types of ANGPTL3 inhibitor drugs are under development, namely monoclonal antibodies, antisense oligonucleotides (ASOs) and CRISPR / Cas9 gene editing, which can promote the hydrolysis of VLDL. Evinacumab is a fully human IgG4 subtype monoclonal antibody targeting ANGPTL3 developed by Regeneron Pharmaceuticals. When used in combination with other lipid-lowering therapies, it can reduce dangerously high cholesterol levels in patients with familial hypercholesterolemia to normal levels. It was approved by the FDA on February 11, 2021 for the treatment of children aged 12 years and above or adults with familial homozygous hypercholesterolemia (Zhang Yue, Li Yue, Wang Li, et al. ANGPTL3 and atherosclerosis [J]. Chinese Journal of Pharmaceutical Biotechnology, 2022, 17(02): 158-163.). Currently, Eli Lilly's monoclonal antibody LY3475766 targeting ANGPTL3 / 8 is in Phase I clinical trials and can significantly reduce the levels of TG and residual cholesterol in the plasma of patients with dyslipidemia. The drugs targeting ANGPTL4 mainly include monoclonal antibody REGN-1001 developed by Regeneron and 14D12 monoclonal antibody developed by Lexicon Pharmaceuticals, both of which are used to lower blood lipids. In addition, there are some innovative drugs targeting ANGPTL3, such as Pfizer's Vupanorsen, an antisense oligonucleotide of ANGPTL3, which can inhibit the synthesis of ANGPTL3 and increase the activity of lipoprotein lipase (LPL), thereby reducing the level of TG-rich lipoprotein (TRL).

[0004] With the development of biopharmaceuticals, various recombinant protein expression platforms are also developing. Among them, CHO cells are one of the most commonly used hosts for expressing recombinant proteins (especially fusion proteins and genetically engineered antibodies) (Haimanti Dorai, Subinay Ganguly. Mammalian cell-produced therapeutic proteins: heterogeneity derived from protein degradation [J]. Curr opin Biotechnol, 2014, 30: 198-204; Wuest DM, Harcum SW, Lee KH. Genomics in mammalian cell culture bioprocessing [J]. Biotechnol Adv, 2012, 30 (3) 629-638.), and the most critical step for the efficient expression of recombinant protein genes in host cells is gene transfection. Currently, the commonly used transfection methods include electrofection, liposome transfection, microinjection, calcium phosphate co-precipitation, etc. (Wang Yueli, Wei Jilou, Cheng Honglei, et al. Research progress of exogenous gene transfection cell technology [J]. Progress in Modern Biomedicine, 2014, 14(7): 1382-138). In the past, the expression of anti-ANGPTL3 humanized monoclonal antibody relied on transient transfection technology, which required complicated extraction and transfection of plasmids each time and unstable expression level, which was not conducive to large-scale industrial production. Compared with other transfection techniques, electrofection has the advantages of simple operation, good repeatability and high transfection efficiency. Electrofection is applicable to almost all cells. However, different electrofection conditions will lead to different transfection efficiencies of exogenous genes. Even if the same cells are transfected under optimal conditions, the transfection efficiency of different exogenous genes will vary (Deng Xiaofen, Yang Xiaojia, Yi Tianhong, et al. Optimization of conditions for electrofection of fusion protein genes and antibody genes in CHO-S cells [J]. Biotechnology Bulletin, 2019, 35(04): 223-228.). Summary of the invention

[0005] The present application introduces anti-ANGPTL3 humanized monoclonal antibody expression vector into host cells by electrotransfection, and finally screens out a series of high expression and stable and controllable cell lines after multiple screenings, thereby completing the present invention.

[0006] In a first aspect, the present invention provides a hybridoma cell, which can stably express an anti-ANGPTL3 humanized monoclonal antibody. The cell is named: anti-ANGPTL3 humanized monoclonal antibody stable cell line (FD36-A44), and the deposit number is: CGMCC No. 46049. The biological deposit is provided to the General Microbiology Center of China National Microbiological Culture Collection Committee (CGMCC).

[0007] In a second aspect, the present invention provides a method for screening cells that stably express anti-ANGPTL3 humanized monoclonal antibodies, the screening method comprising the following steps:

[0008] S1. Design primers based on the anti-ANGPTL3 humanized monoclonal antibody sequence, and use the genome as a template to amplify the ANGPTL3 gene fragment, clone the ANGPTL3 gene fragment into a vector, and obtain the recombinant plasmid pKS001-FD36;

[0009] S2. The recombinant plasmid obtained in S1 is mixed with host cells and then transfected. The transfected cells are cultured in medium A and diluted to medium B after two days;

[0010] S3. Using a culture medium without glutamine component and MSX to screen cell lines expressing anti-ANGPTL3 humanized monoclonal antibodies, finally screening out the cell lines of the present invention that highly express and stably controllable anti-ANGPTL3 humanized monoclonal antibodies.

[0011] Further, in step S1, the sequence of the anti-ANGPTL3 humanized monoclonal antibody is its amino acid sequence.

[0012] Furthermore, the heavy chain amino acid sequence of the anti-ANGPTL3 humanized monoclonal antibody is shown in SEQ ID NO: 1, and the light chain amino acid sequence is shown in SEQ ID NO: 2.

[0013] Further, in step S1, the primers are designed after converting the amino acid sequence of the anti-ANGPTL3 humanized monoclonal antibody into the corresponding nucleotide sequence.

[0014] Furthermore, in step S1, the cloning method is IN-FUSION technology.

[0015] Further, in step S2, the host cell is a eukaryotic cell.

[0016] Preferably, the host cell is CHO-K1Q.

[0017] Further, in step S2, the A culture medium is CHO CD02+glutamine culture medium, and the B culture medium is CHO CD02+methionine sulfoximide culture medium.

[0018] Furthermore, in step S3, the screening method includes five steps: Gln-free culture screening, MSX pressure screening, batch culture screening, shake flask feeding process screening and secondary subclone screening.

[0019] In a third aspect, the present invention provides a humanized monoclonal antibody against ANGPTL3, wherein the monoclonal antibody is secreted by the hybridoma cell of the first aspect.

[0020] In a fourth aspect, the present invention provides an antibody conjugate, wherein the conjugate comprises the monoclonal antibody described in the third aspect.

[0021] In a fifth aspect, the present invention provides use of the monoclonal antibody described in the third aspect in preparing a reagent for detecting ANGPTL3.

[0022] In a sixth aspect, the present invention provides a kit for detecting ANGPTL3, wherein the kit comprises the monoclonal antibody described in the third aspect.

[0023] Furthermore, the kit may be one or more of an ELISA detection kit, a colloidal gold detection kit, an immunohistochemistry kit, an immunofluorescence kit and / or an in situ hybridization staining kit.

[0024] Furthermore, the diagnostic method of the kit includes one or more of a direct method, an indirect method, a double antibody sandwich method and / or a competitive method.

[0025] In a seventh aspect, the present invention provides use of the monoclonal antibody described in the third aspect or the antibody conjugate described in the fourth aspect in the preparation of a medicament for preventing and / or treating kidney disease or metabolic-related diseases.

[0026] Furthermore, the kidney disease includes, but is not limited to, various kidney diseases accompanied by proteinuria and podocyte damage such as minimal change disease, focal segmental glomerulosclerosis, diabetic nephropathy, IgA nephropathy, Henoch-Schonlein purpura nephropathy and lupus nephropathy.

[0027] Furthermore, the metabolism-related diseases include, but are not limited to, diabetes and dyslipidemia diseases such as hypercholesterolemia and hypertriglyceridemia.

[0028] The high expression and stable and controllable cell line in the present invention is named: anti-ANGPTL3 humanized monoclonal antibody stable cell line (FD36-A44), with the deposit number: CGMCC No.46049. It was provided with the General Microbiology Center of China Microorganism Culture Collection Administration (CGMCC) for biological deposit on September 23, 2024. The deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0029] Beneficial Effects

[0030] The present invention prepares a series of cells expressing anti-ANGPTL3 humanized monoclonal antibodies, and then screens out an anti-ANGPTL3 humanized monoclonal antibody cell line with high expression level and stable and controllable advantages. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Screening process for stable cell lines.

[0032] Figure 2 Evaluate expression assay results for minipool plates.

[0033] Figure 3 Evaluate expression assay results for minipool shake flasks.

[0034] Figure 4 Expression assay results were evaluated in minipool shake flask fed-batch assays.

[0035] Figure 5 The master clone was fed and purified for yield.

[0036] Figure 6 Feed culture viable cell density and cell viability for the main clone.

[0037] Figure 7 Evaluate expression assay results for subcloning plates.

[0038] Figure 8 Evaluation of expression assay results for subcloning shake flasks.

[0039] Fig. 9 Evaluate expression assay results for subcloning feeds.

[0040] Fig.10 The purification yields of subclones and their corresponding main clones are shown in Table 2.

[0041] Fig.11 Feed culture viable cell density and cell viability for subcloning.

[0042] Fig.12 Shown are the SDS-PAGE results of the subclone and its corresponding main clone protein product. DETAILED DESCRIPTION

[0043] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0044] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0045] Explanation of terms

[0046] Transient transfection: refers to the introduction of the constructed plasmid into mammalian cells in some way. The exogenous gene on the plasmid is not integrated into the cell's own genome. This entire process of rapid transfection to obtain protein is called transient transfection expression.

[0047] Electroporation transfection method: (Electroporation method) The structure of the cell membrane is changed by applying an external current, so that the cell membrane produces instantaneous, reversible nanoscale water-filled holes, which promotes the entry of exogenous molecules into the cell. The electroporation transfection method is simple and fast to operate. It only needs to prepare a cell suspension for electroporation. The entire transfection process takes less than 1 second. Theoretically, by optimizing the electroporation conditions, better transfection effects can be obtained in various types of cells, and a large number of cells can be transfected in batches. It is worth noting that the solution system for electroporation transfection needs to be as free of inorganic salts as possible, because the presence of salts may cause arc discharge, affect cell viability, and even cause cell death.

[0048] Seamless cloning: (IN-FUSION) is a new technology that is significantly different from the traditional enzyme cutting and ligation method. This technology is a gene cloning technology that relies on homologous sequences and is simple, fast and efficient. Through the action of recombinase, any DNA fragment containing the overlapping region at the end of the vector can be recombined into a linearized vector without being restricted by enzyme cutting sites, and the background of vector self-ligation is extremely low.

[0049] Heavy Chain: The type of heavy chain defines the class of antibody. There are five types of mammalian Ig heavy chains, represented by the Greek letters: α, δ, ε, γ, and μ. These heavy chains are found in IgA, IgD, IgE, IgG, and IgM antibodies. The size and composition of heavy chains vary, with α and γ containing approximately 450 amino acids, and μ and ε containing approximately 550 amino acids. Each heavy chain has two regions: a constant region and a variable region.

[0050] Light chain: There are only two types of light chains in mammals, λ and κ. Light chains have two consecutive domains: a constant domain and a variable domain. The length of a light chain is about 211-217 amino acids. The two light chains contained in each antibody are usually identical.

[0051] Example 1 Construction of anti-ANGPTL3 humanized monoclonal antibody expression vector

[0052] The amino acid sequence of the anti-ANGPTL3 humanized monoclonal antibody (FD36) (the heavy chain amino acid sequence of FD36 is shown in SEQ ID NO: 1, and the light chain amino acid sequence of FD36 is shown in SEQ ID NO: 2) is converted into the corresponding nucleotide sequence and then subjected to gene synthesis. Upstream and downstream primers are designed to perform PCR amplification on the gene fragment and the vector, thereby achieving DNA linearization and the addition of sticky ends. The gene fragment and the vector are connected by IN-FUSION (seamless cloning) technology to achieve the construction of the pKS001-FD36 plasmid. The constructed plasmid is verified by sequencing and then amplified and prepared in large quantities for subsequent steps.

[0053] Example 2 Introduction of anti-ANGPTL3 humanized monoclonal antibody expression vector into host cells

[0054] recovery CHO-K1Q working cell bank cells are used to construct engineering cell lines. Cultivate cells with CHO CD02 culture medium supplemented with 4mM L-glutamine. Inoculate cells and culture for 3 days before passage or direct transfection. During transfection, mix pKS001-FD36 plasmid and CHO-K1Q cells evenly and then electrotransfect. After transfection, place cells in CHO CD02+4mM L-glutamine medium and culture them two days later. Dilute to CHO CD02 medium supplemented with L-methionine sulfoximide to start screening.

[0055] Example 3 Screening of stable cell lines of anti-ANGPTL3 humanized monoclonal antibodies

[0056] 3.1 Experimental methods

[0057] The recombinant FD36 strain was screened using CHO CD02 and MSX culture media without glutamine components. Glutamine is an amino acid that plays an important role in cell growth and reproduction in cell culture. It not only participates in cell energy metabolism, but also participates in protein synthesis and nucleic acid metabolism. In the absence or insufficient supply of glutamine, glutamine synthetase (GS) catalyzes glutamate and ammonium ions to synthesize glutamine, which supplies cell metabolism and protein synthesis. MSX is a competitive inhibitor of GS activity. After MSX binds to the glutamate site of GS, it will be phosphorylated by ATP, thereby irreversibly inhibiting GS activity. The vector carries the linked GS gene and FD36 gene. A small amount of the vector is integrated into the host cell genome after transfection. Cells without the FD36 gene and cells expressing low levels of glutamine synthetase will not survive. Only cells expressing high levels of glutamine synthetase genes can survive, thereby screening out cell lines with high expression of the FD36 gene.

[0058] During the entire screening process, the recombinant FD36 stable cell line underwent five screening steps, including serum-free, animal-derived component-free, stable cell line underwent serum-free, animal-derived component-free, glutamine-free medium CHO CD02 screening, MSX pressure screening, batch culture screening, shake flask flow-batch process screening, and secondary subclone screening (see Figure 1 ).

[0059] 3.2 Experimental Results

[0060] 3.2.1 Minipool clone evaluation and screening

[0061] Well plate evaluation: After transfection, cells were diluted and cultured. After the minipool clones were grown to a certain abundance, the yield was detected by ELISA to select high-expressing cell lines. A total of 353 clones were screened, of which 235 clones had a yield of 0-11 mg / L and 118 clones had a yield of 3.95-55.83 mg / L. The latter were used for expanded evaluation ( Figure 2 ).

[0062] Shake flask evaluation: Among the 118 clones, 3 clones were abandoned due to poor growth, and the remaining 115 clones continued to be cultured in shake flasks. The yields of 76 clones were between 0 and 50 mg / L, 19 clones were between 50 and 82 mg / L, and 20 clones were between 82 and 296 mg / L. The 20 clones with the highest yields were used for feeding culture screening ( Figure 3 ).

[0063] Shake flask fed-batch evaluation: After the above 20 clones were cultured in shake flasks, the expression levels were detected by ELISA and ranked. The three clones with the highest production, FD36-34, FD36-36 and FD36-37, were selected as the main clones for further evaluation ( Figure 4 ).

[0064] Evaluation of master clones: After the above three master clones were cultured, the cell supernatant was taken for protein purification and the yield was evaluated by UV quantitative analysis. The results showed that the yield of FD36-34 was 801.17 mg / L, the yield of FD36-36 was 886.1 mg / L, and the yield of FD36-37 was 825.36 mg / L ( Figure 5 ); and monitored the live cell density and cell viability of the feed culture. The results showed that within 6-8 days of the normal protein expression cycle, all three clones showed high live cell density and cell viability ( Figure 6 ), after comprehensive consideration, FD36-36 with the highest expression level was finally selected as the main cloning target strain for subsequent subclone screening.

[0065] 3.2.2 Subclone evaluation and screening

[0066] Well plate evaluation: After limiting dilution culture of the above FD36-36 main clone target strain, a total of 244 clones were screened, 152 clones with a yield of 0-39.8 mg / L, and 92 clones with a yield of 14.5-92 mg / L, the latter of which were used for expanded evaluation ( Figure 7 ).

[0067] Shake bottle evaluation: Among the 92 clones, 44 clones had a yield of 267-500 mg / L, 30 clones had a yield of 500-644 mg / L, and 18 clones had a yield of 661-994 mg / L. Among the 18 clones with the highest yield, 3 clones were abandoned due to poor growth, and the remaining 15 clones were used for feeding culture screening ( Figure 8 );

[0068] Shake flask fed-batch evaluation: After the 15 clones were cultured in shake flasks, their expression levels were detected by ELISA and ranked. The three subclones with the highest production, FD36-A44, FD36-A90 and FD36-A06, and their corresponding main clone FD36-36 were selected for further evaluation ( Fig. 9 );

[0069] Subclone evaluation: After the above three subclones and their corresponding main clones were cultured, the cell supernatants were taken for protein purification and the yield was evaluated by UV quantitative analysis. The results showed that the yield of the main clone FD36-36 was 2405.55 mg / L, the yield of the subclone FD36-A44 was 3177.90 mg / L, the yield of the subclone FD36-A90 was 2949.43 mg / L, and the yield of the subclone FD36-A06 was 2473.07 mg / L ( Fig.10 ); and monitored the live cell density and cell viability of the feed culture. The results showed that within 6-8 days of the normal protein expression cycle, the three subclones showed high live cell density and cell viability ( Fig.11 ); SDS-PAGE showed that the molecular weight of the above protein product was in line with expectations and the purity was good ( Fig.12 ).

Claims

1. A hybridoma cell line, which can stably express an anti-ANGPTL3 humanized monoclonal antibody. The cell line is named: anti-ANGPTL3 humanized monoclonal antibody stable cell line (FD36-A44), and the deposit number is: CGMCC No.46049. The cell line has been provided with the General Microbiology Center of China Microbiological Culture Collection Administration (CGMCC) for biological deposit.

2. A method for screening cells that stably express an anti-ANGPTL3 humanized monoclonal antibody, the screening method comprising the following steps: S1. Design primers based on the anti-ANGPTL3 humanized monoclonal antibody sequence, and use the genome as a template to amplify the ANGPTL3 gene fragment, clone the ANGPTL3 gene fragment into a vector, and obtain the recombinant plasmid pKS001-FD36; S2. The recombinant plasmid obtained in S1 is mixed with host cells and then transfected. The transfected cells are cultured in medium A and diluted to medium B after two days; S3. Using a culture medium without glutamine component and MSX to screen cell lines expressing anti-ANGPTL3 humanized monoclonal antibodies, finally screening out the cell lines of the present invention that highly express and stably controllable anti-ANGPTL3 humanized monoclonal antibodies.

3. The screening method according to claim 2, wherein in step S1, the sequence of the anti-ANGPTL3 humanized monoclonal antibody is its amino acid sequence; the heavy chain amino acid sequence of the anti-ANGPTL3 humanized monoclonal antibody is shown in SEQ ID NO: 1, and the light chain amino acid sequence is shown in SEQ ID NO: 2; and the primers are designed after converting the amino acid sequence of the anti-ANGPTL3 humanized monoclonal antibody into the corresponding nucleotide sequence; In step S2, the host cell is CHO-K1Q, the A medium is CHO CD02+glutamine medium, and the B medium is CHO CD02+methionine sulfoximide medium; In step S3, the screening method includes five steps: Gln-free culture screening, MSX pressure screening, batch culture screening, shake flask feeding process screening and secondary subclone screening.

4. A humanized monoclonal antibody against ANGPTL3, wherein the monoclonal antibody is secreted by the hybridoma cell according to claim 1.

5. An antibody conjugate, comprising the monoclonal antibody according to claim 3.

6. Use of the monoclonal antibody according to claim 3 in the preparation of a reagent for detecting ANGPTL3.

7. A kit for detecting ANGPTL3, comprising the monoclonal antibody according to claim 3.

8. The kit according to claim 7, wherein the kit can be one or more of an ELISA detection kit, a colloidal gold detection kit, an immunohistochemistry kit, an immunofluorescence kit and / or an in situ hybridization staining kit.

9. Use of the monoclonal antibody according to claim 3 or the antibody conjugate according to claim 4 in the preparation of a drug for preventing and / or treating kidney disease or metabolic-related diseases.

10. The use as claimed in claim 9, wherein the kidney disease includes but is not limited to various kidney diseases accompanied by proteinuria and podocyte damage such as minimal change disease, focal segmental glomerulosclerosis, diabetic nephropathy, IgA nephropathy, Henoch-Schonlein purpura nephropathy and lupus nephropathy; the metabolic-related diseases include but are not limited to diabetes and dyslipidemia diseases such as hypercholesterolemia and hypertriglyceridemia.

Citation Information

Patent Citations

  • CHO cell strain containing recombinant human epidermal growth factor acceptor antibody gene, and screening method and production technology thereof

    CN108220244A

  • TRI-variable domain binding proteins and uses thereof

    WO2012088290A2

  • Anti-angptl3 antibody or antigen-binding fragment thereof, preparation method therefor and use thereof

    WO2022205021A1